Clinical evidence supports these findings; for example, SGLT2 inhibitor use was associated with a lower risk of incident HCC in patients with coexisting T2DM and chronic hepatitis B infection [69]. The gene discussed is SLC5A2; the disease is hepatocellular carcinoma.